The U.S. Food and Drug Administration approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for patients with EGFR-mutated locally advanced or metastatic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE